Drug-resistant tuberculosis: how to interpret rapid molecular test results
Abstract: This training toolkit by the European Laboratory Initiative for TB, HIV and Viral Hepatitis provides a unique combination of practical guidance and expert advice on the interpretation of selected WHO-endorsed tests for drug-resistant tuberculosis (DR-TB). More specifically, it covers the latest guidance for the interpretation of rapid molecular assays for DR-TB by Cepheid (GeneXpert MTB/RIF and GeneXpert MTB/RIF Ultra) and Hain Lifescience (GenoTypeMTBDRplus VER 2.0 and GenoTypeMTBDRsl VER 2.0). Participants can exchange experiences through a course forum. Laboratory experts are available to address key questions via the forum and a dedicated pilot email service. The course is particularly relevant for laboratory experts who perform drug-susceptibility testing (DST) for TB and clinicians who use DST results in their routine clinical practice. We hope this training will help refine your practice, thereby strengthening the global capacity to diagnose DR-TB.

Course available here: https://openwho.org/courses/multi-drug-resistant-tb
Author(s): WHO
Resource Type: Training Materials
Source: World Health Organization
Go to Top